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Biomarker-stratified clinical trials assess the biomarker sig-
nature of subjects and split them into subgroups so that
treatment is of benefit to those who are likely to respond.
Since multiple hypotheses are tested, it becomes important
to control the type I error. Current methods control the
false positive rate where one rejects the null hypothesis
while in reality that was true. For two subgroups, the false
positive rate is controlled across the two hypotheses as a
Family Wise Error Rate (FWER) to an overall predeter-
mined significance level.
The concept of “Wrong Positive” rate is presented where
one rejects the null hypothesis in one subgroup while in
reality the efficacy would be in the other subgroup.
Controlling the wrong positives as well as false positives to
an overall significance level constitutes a strong FWER.
Further options exist for control of Individual Outcome
FWER by assigning weighting to reject the respective null
hypotheses.
We apply our methodology to an optimal biomarker-
stratified Simon two-stage cancer clinical trial design
and illustrate the variation in minimum expected sample
sizes for different choices of type I controls for a range
of operating characteristics. While the weak FWER
would suit a phase II trial, additionally controlling the
wrong positives could be more appropriate in a confir-
matory setting. The chosen design is an adaptive enrich-
ment that evaluates efficacy in biomarker-positive as
well as biomarker-negative subpopulations, and optimal
designs are obtained using the four different choices of
type I error controls: weak or strong FWER with or
without individual outcomes.
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